AstraZeneca and Bristol Myers Squibb discuss merger.
AstraZeneca and Bristol Myers Squibb are discussing a merger. The deal would make a large pharmaceutical company. The merger is worth around $400 billion.
The companies are talking about combining their businesses. This would create a major player in the pharmaceutical industry. The potential merger is valued at approximately $400 billion. Concerns about antitrust regulations could make the deal difficult. The merger is happening because many drug patents are about to expire.
Summarized from the sources above. Read the originals for the full story.
Highlights
Companies Discuss Merger
AstraZeneca and Bristol Myers Squibb are talking about a possible merger.
Deal Value is High
The merger could be worth around $400 billion.
Antitrust Concerns Exist
The merger might face problems with rules about competition.
Large Pharmaceutical Company
The combined company would be a major player in the industry.
Patent Expirations Drive Deal
The merger is happening because drug patents are expiring soon.
Perspectives
- AstraZeneca and Bristol Myers Squibb are discussing a merger.
- The merger would create a large pharmaceutical company.
- The deal is valued at approximately $400 billion.
- The merger is part of a trend of consolidation in the industry.
Sources say the merger is worth $400 billion.
EurActiv, EU, El País, ANSA, Financial Times
Sources say the merger is worth $347 billion.
New